Found: 28
Select item for more details and to access through your institution.
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 916, doi. 10.1111/dom.14962
- By:
- Publication type:
- Article
Oral insulin: A history of ambition, failure and data torturing.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 940, doi. 10.1111/dom.14984
- By:
- Publication type:
- Article
Association of long‐term hyperglycaemia and insulin resistance with brain atrophy and cognitive decline: A longitudinal cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1091, doi. 10.1111/dom.14958
- By:
- Publication type:
- Article
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1130, doi. 10.1111/dom.14957
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1080, doi. 10.1111/dom.14956
- By:
- Publication type:
- Article
Validation of a diet‐induced Macaca fascicularis model of non‐alcoholic steatohepatitis with dietary and pioglitazone interventions.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1068, doi. 10.1111/dom.14955
- By:
- Publication type:
- Article
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1125, doi. 10.1111/dom.14954
- By:
- Publication type:
- Article
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1056, doi. 10.1111/dom.14952
- By:
- Publication type:
- Article
Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 901, doi. 10.1111/dom.14953
- By:
- Publication type:
- Article
Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1045, doi. 10.1111/dom.14951
- By:
- Publication type:
- Article
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1032, doi. 10.1111/dom.14950
- By:
- Publication type:
- Article
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1024, doi. 10.1111/dom.14949
- By:
- Publication type:
- Article
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1011, doi. 10.1111/dom.14948
- By:
- Publication type:
- Article
Changes in the use of glucose‐lowering drugs: A Danish nationwide study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1002, doi. 10.1111/dom.14947
- By:
- Publication type:
- Article
A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 992, doi. 10.1111/dom.14946
- By:
- Publication type:
- Article
Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 985, doi. 10.1111/dom.14945
- By:
- Publication type:
- Article
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 975, doi. 10.1111/dom.14944
- By:
- Publication type:
- Article
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS‐1 to ‐5 studies
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 965, doi. 10.1111/dom.14943
- By:
- Publication type:
- Article
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1112, doi. 10.1111/dom.14936
- By:
- Publication type:
- Article
Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1117, doi. 10.1111/dom.14941
- By:
- Publication type:
- Article
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 961, doi. 10.1111/dom.14940
- By:
- Publication type:
- Article
Current insulin infusion set failure criteria may be too stringent for real‐life settings and may skew infusion set failure outcomes in extended‐wear infusion set studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1106, doi. 10.1111/dom.14935
- By:
- Publication type:
- Article
Comparison of faster‐acting aspart with insulin aspart under conditions mimicking underestimation or missed meal boluses in type 1 diabetes using closed‐loop insulin delivery.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
A retrospective analysis of 24‐month real‐world glucose control for children and adolescents with type 1 diabetes using the MiniMed™ 670G insulin pump.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1101, doi. 10.1111/dom.14934
- By:
- Publication type:
- Article
Safety and efficacy of an oral insulin (Capsulin) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 953, doi. 10.1111/dom.14922
- By:
- Publication type:
- Article
Sodium‐glucose cotransporter‐2 inhibitor prescribing practices.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1136, doi. 10.1111/dom.14931
- By:
- Publication type:
- Article
Oral insulin (ORMD‐0801) in type 2 diabetes mellitus: A dose‐finding 12‐week randomized placebo‐controlled study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 943, doi. 10.1111/dom.14901
- By:
- Publication type:
- Article
Diabetes, Obesity and Metabolism.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 899, doi. 10.1111/dom.14751
- Publication type:
- Article